Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

226R-1

Sigma-Aldrich

BCL2 (E17) Rabbit Monoclonal Primary Antibody

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

E17, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (226R-14)
vial of 0.5 mL concentrate (226R-15)
bottle of 1.0 mL predilute (226R-17)
vial of 1.0 mL concentrate (226R-16)
bottle of 7.0 mL predilute (226R-18)

Produttore/marchio commerciale

Cell Marque™

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

Isotipo

IgG

Controllo

tonsil

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

cytoplasmic

Informazioni sul gene

human ... BCL2(596)

Categorie correlate

Descrizione generale

Anti-BCL2 has shown consistent negative reaction on reactive germinal centers and positive staining of neoplastic follicles in follicular lymphoma. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. This antibody may also be used in distinguishing between those follicular lymphomas that express BCL2 protein and the small number in which the neoplastic cells are BCL2 negative.

Linkage

BCL2 Positive Control Slides, Product No. 226S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota sulla preparazione

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Y Tsujimoto et al.
Proceedings of the National Academy of Sciences of the United States of America, 83(14), 5214-5218 (1986-07-01)
We have determined that the bcl-2 (B-cell leukemia/lymphoma 2) gene is transcribed into three overlapping mRNAs, and we have cloned bcl-2 cDNA sequences. Sequence analysis of the bcl-2 cDNA clones and comparison of their sequences to their genomic counterparts indicate
D Hockenbery et al.
Nature, 348(6299), 334-336 (1990-11-22)
The t(14; 18) chromosomal translocation of human follicular B-cell lymphoma juxtaposes the bcl-2 gene with the immunoglobulin heavy chain locus. The bcl-2 immunoglobulin fusion gene is markedly deregulated resulting in inappropriately elevated levels of bcl-2 RNA and protein. Transgenic mice
J W Moul
European urology, 35(5-6), 399-407 (1999-05-15)
Within the past 5 years, research has increasingly addressed molecular alterations in prostate cancer (CaP). Mutations of tumor suppressor gene p53 have been found in a variety of cancers, including urologic neoplasms. Several studies have been conducted on CaP specimens
B Martin et al.
British journal of cancer, 89(1), 55-64 (2003-07-03)
The role of the anti-apoptotic protein Bcl-2 in lung cancer remains controversial. In order to clarify its impact on survival in small and non-small cell lung cancer (NSCLC), we performed a systematic review of the literature. Trials were selected for
D R Ciocca et al.
Endocrine, 13(1), 1-10 (2000-10-29)
Tamoxifen is one of the most effective treatments for breast cancer. Standard practice is to select patients who are likely to respond to this therapy through the evaluation of estrogen receptor (ER) and progesterone receptor (PR) in the primary tumor
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.